POU2F3 antibody - N-terminal region (ARP32537_T100)
- Known as:
- POU2F3 (anti-) - N-terminal region (ARP32537_T100)
- Catalog number:
- arp32537_t100
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- POU2F3 antibody - N-terminal region (ARP32537_T100)
Related genes to: POU2F3 antibody - N-terminal region (ARP32537_T100)
- Gene:
- POU2F3 NIH gene
- Name:
- POU class 2 homeobox 3
- Previous symbol:
- -
- Synonyms:
- OCT11, PLA-1, Skn-1a, Epoc-1
- Chromosome:
- 11q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 2002-11-28
- Date modifiied:
- 2014-11-19
Related products to: POU2F3 antibody - N-terminal region (ARP32537_T100)
Related articles to: POU2F3 antibody - N-terminal region (ARP32537_T100)
- Small cell neuroendocrine carcinomas occur in both pulmonary (SCLC) and extrapulmonary sites (EP-SCNC). Although morphologically similar, they may differ biologically, but these differences are not well characterized. The aim of this study was to compare cohorts of SCLC (n = 215) and EP-SCNC(n = 184) with respect to molecular alterations, RNA and protein expression in tumor tissue. The median survival for SCLC was 6.3 months and 8.9 months for EP-SCNC patients (p < 0.0001). Genetic alterations of TP53, RB1, and KMT2D were the most common in both groups. The TP53 mutation was associated with worse survival in EP-SCNC (HR = 1.62; p = 0.043), while KMT2D was associated with worse survival in SCLC (HR = 1.62; p = 0.003). The tumor mutation burden (TMB) was higher in SCLC (p < 0.001). In RNA-Seq analyses, SCLC and EP-SCNC formed distinct RNA clusters. A total of 553 genes were differentially expressed. snoRNAs and tRNAs were predominantly upregulated in SCLC. GOAT analysis revealed upregulation in cell signaling and cellular plasticity in EP-SCNC, whereas SCLC showed enhanced transcriptional activity, including RNA processing and nuclear functions. Immunohistochemistry revealed higher expression of ASCL1 and NEUROD1 in SCLC than in EP-SCNC. YAP1 and POU2F3 expressions were higher in EP-SCNC. In multivariate analyses, EP-SCNC was associated with better survival, greater molecular heterogeneity, and distinct genetic, transcriptional, and immunohistochemical profiles. These findings demonstrate that, despite their morphological similarity, the two tumor groups are biologically distinct. - Source: PubMed
Publication date: 2026/05/25
Pavlíčková KláraHojný JanHájková NikolaWaldauf PetrDundr PavelDrosslerová MarieŠvajdler MariánFabian PavelStružinská IvanaKrkavcová EvaDvořák JiříMichálková RomanaZambo Iva StaniczkováFlídrová MiroslavaLaco JanHornychová HelenaDelongová PatricieŠkarda JozefHrudka JanMatěj Radoslav - Tuft cells are rare, chemosensory epithelial cells present in various tissues, including the respiratory and gastrointestinal tracts. Recent studies have revealed their significant role in cancer biology, particularly through the expression of the transcription factor POU2F3, which serves as a master regulator of tuft cell lineage. In several cancer types, including small cell lung cancer, gastric cancer, and breast cancer, POU2F3 expression defines a distinct molecular subtype termed "tuft cell-like" tumors. These tumors exhibit unique transcriptional programs and altered tumor-immune interactions, contributing to their distinct therapeutic sensitivities. In this review, we first analyze the expression patterns of POU2F3 across cancer types using the TCGA datasets, revealing differential expression profiles and supporting the classification of tuft cell-like subtypes. We further explore cancer-type-specific signaling pathways regulating tuft cell differentiation and function, such as IL-25, acetylcholine, and taste receptor-related pathways. Finally, we propose that tuft cell-like signatures may serve as promising biomarkers for diagnosis, prognosis, and treatment stratification. Understanding the tuft cell-like-POU2F3 axis could open new avenues for targeted therapies in lineage-defined cancers. - Source: PubMed
Publication date: 2025/11/14
Ye MenglingLiu YuyangLi Hui - High-grade neuroendocrine carcinoma (NEC) can be difficult to diagnose, particularly when conventional neuroendocrine (NE) markers are weakly expressed or absent. This challenge is particularly pronounced in NE-low tumors with lineage-defining transcription factor profiles (e.g., POU2F3 and/or YAP1), which may exhibit squamoid (basal-like) morphology and reduced or absent expression of synaptophysin (Syn), chromogranin A (CgA), and CD56, thereby phenotypically overlapping with non-small cell lung cancer (NSCLC) and increasing the risk of misclassification. In this case, needle biopsies from the lung and liver both showed a poorly differentiated carcinoma with squamoid morphology and squamoid/basal-like immunohistochemical features. Syn, CgA, and CD56 were negative in both specimens, leading to an initial diagnosis of poorly differentiated squamous cell carcinoma. However, the subsequent clinical course revealed discordant clinicobiologic features, including rapid progression of the liver metastases, markedly elevated NSE levels, and a high Ki-67 labeling index (60-80%). These discrepancies prompted further molecular evaluation, and 90-gene expression profiling (90-GEP) supported a neuroendocrine lineage assignment. Retrospective immunohistochemistry further demonstrated positivity for POU2F3 and YAP1, whereas INSM1 was negative in both specimens, supporting classification as an NE-marker-negative high-grade NEC with an NE-low NEC/SCLC-like lineage profile. The patient subsequently showed a marked response to etoposide plus carboplatin, consistent with the known chemosensitivity of high-grade NEC/SCLC to platinum-based chemotherapy. This case highlights an underrecognized diagnostic pitfall of NE-marker-negative high-grade NEC with squamoid mimicry. When morphology, immunophenotype, and clinical behavior are discordant, integration of expanded immunohistochemistry (including lineage-defining transcription factors), molecular lineage assays (e.g., GEP), and treatment response may help avoid misdiagnosis and guide appropriate therapy. - Source: PubMed
Publication date: 2026/05/08
He WenTang YingLi YanZhang JianfengYou XuyangWu Qiaozhen - Heterogeneity of neuroendocrine (NE) differentiation in pulmonary high-grade NE carcinoma, mainly small-cell lung cancer (SCLC), has been recently explored based on the expression of lineage transcription factors such as ASCL1, NEUROD1 and POU2F3. However, molecular classification based on these factors remains incomplete, and NE differentiation in lung cancers is more heterogeneous than previously appreciated. Here, we investigated the heterogeneity of NE differentiation using epigenomic profiling across a range of lung cancers with NE components, predominantly large-cell neuroendocrine carcinoma (LCNEC). - Source: PubMed
Publication date: 2026/05/18
Sato TakashiHamamoto JunkoEmoto KatsuraNagashio RyoYagami YuriYamamoto HirokiInoue RyosukeMatsuo HiromiShirasawa MasayukiKuchitsu YukiKawano ShinHara YuichiroYoo SeungyeulFukushima TakahiroSugihara KaiTerai HidekiSanoyama ItaruMurakumo YoshikiDomoto HideharuHaraguchi-Hashiguchi MizuhaShiomi KazuMikubo MasashiYasuda HiroyukiWatanabe HideoNaoki Katsuhiko - This study aimed to investigate the clinicopathological features, treatment strategies and outcomes, failure patterns, and prognostic factors impacting progression-free survival (PFS) and overall survival (OS) in patients with extensive-stage primary small cell esophageal carcinoma (ES-SCEC). - Source: PubMed
Publication date: 2026/05/18
Liu DiZhang XiaofeiZhang JunhuaZhao KuaileXiang JiaqingZhang ZhenZhang Yiliang